Q-omics provides the consensus-scored CALM3 profile across patient tissues and cancer cell-line models. CALM3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CALM3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CALM3 RNA expression shows 18,966 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where CALM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALM3 survival associations across molecular data types. CALM3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALM3 RNA expression–survival associations across cancer types. High CALM3 expression shows unfavorable associations in MESO, LUAD, ACC, LUSC and SKCM, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CALM3 RNA expression.
This table summarizes CALM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CALM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALM3 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, BRCA and CHOL. The HNSC box plot shows higher CALM3 RNA expression in tumor versus normal tissue (log2 FC = +1.012, t-test p < 0.001).
This table shows molecular features associated with CALM3 in patient tissues and cancer cell lines. In patient samples, CALM3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CALM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
